---
title: "Harvard Bioscience | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 23.7 M"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275458109.md"
datetime: "2026-02-10T12:32:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275458109.md)
  - [en](https://longbridge.com/en/news/275458109.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275458109.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275458109.md) | [繁體中文](https://longbridge.com/zh-HK/news/275458109.md)


# Harvard Bioscience | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 23.7 M

Revenue: As of FY2025 Q4, the actual value is USD 23.7 M, beating the estimate of USD 23.1 M.

#### Preliminary Fourth Quarter 2025 Financial Highlights

Harvard Bioscience, Inc. expects to report preliminary fourth quarter revenue of $23.7 million, which is above the midpoint of its guidance range of $22.5 million to $24.5 million . Gross Margin is expected to be 60%, reaching the high end of the 58% to 60% guidance range, attributed to an improved mix towards higher margin product lines and benefits from prior cost reductions . Adjusted EBITDA is anticipated to be $3.8 million, marking a 27% year-over-year growth, driven by cost reduction, improved expense management, and solid execution .

#### Outlook for 2026

For 2026, Harvard Bioscience, Inc. expects year-over-year revenue growth . The company also anticipates mid-to high-single-digit adjusted EBITDA growth for 2026 .

### 相关股票

- [Harvard Bioscience (HBIO.US)](https://longbridge.com/zh-CN/quote/HBIO.US.md)

## 相关资讯与研究

- [Harvard Bioscience Q4 revenue falls 3%, reports net loss](https://longbridge.com/zh-CN/news/278875728.md)
- [Gamehaus Holdings Inc. to Announce Unaudited Financial Results for the Second Quarter of Fiscal 2026 on March 23, 2026 | GMHS Stock News](https://longbridge.com/zh-CN/news/278368804.md)
- [09:23 ETOxford Education entre las empresas de más rápido crecimiento de Europa](https://longbridge.com/zh-CN/news/278565101.md)
- [Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering | DNTH Stock News](https://longbridge.com/zh-CN/news/278647604.md)
- [These Analysts Cut Their Forecasts On Kohl's Following Q4 Earnings](https://longbridge.com/zh-CN/news/278743577.md)